TY  - GEN
AU  - Laguno, M
AU  - Von Wichmann, MA
AU  - Van den Eynde, E
AU  - Navarro, J
AU  - Cifuentes Luna, Carmen
AU  - Murillas Angoiti, Javier
AU  - Veloso, S
AU  - Martinez-Rebollar, M
AU  - Guardiola, JM
AU  - Jou, A
AU  - Gomez-Sirvent, J. L
AU  - Cervantes, M
AU  - Pineda, JA
AU  - Lopez-Calvo, S
AU  - Carrero, A
AU  - Montes, ML
AU  - Deig, Elisabeth
AU  - Tapiz, A
AU  - Ruiz-Mesa, JD
AU  - Cruceta, A
AU  - de Lazzari, Ellsa
AU  - Mallolas, J
PY  - 2016
DO  - 10.1016/j.ijid.2016.10.028
SN  - 1201-9712
UR  - http://hdl.handle.net/20.500.12105/20233
AB  - Introduction: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-alpha 2a/ribavirin (PEG-IFN/RBV) in the retreatment...
LA  - eng
PB  - Elsevier
KW  - PEG-IFN/RBV plus BOC therapy
KW  - HIV-HCV experienced patients
KW  - HCV genotype 1
KW  - Re-treatment
KW  - Viral Nonstructural Proteins
KW  - Genotype
KW  - Hepacivirus
KW  - Retreatment
KW  - Polyethylene Glycols
KW  - Spain
KW  - Adult
KW  - Antiviral Agents
KW  - Hepatitis C
KW  - Humans
KW  - Drug Therapy, Combination
KW  - Middle Aged
KW  - Recombinant Proteins
KW  - HIV Infections
KW  - Male
KW  - Prospective Studies
KW  - Female
KW  - Coinfection
KW  - Treatment Outcome
KW  - Proline
KW  - Interferon-alpha
KW  - Ribavirin
TI  - Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study
TY  - research article
ER  -